Hisamitsu Pharmaceutical announced that it would conduct a management buyout (MBO) to delist from the stock exchange. The company's CEO's asset management company will acquire all shares via tender offer at 6,082 yen per share, for a total transaction value of approximately 3.9 trillion yen. The MBO was completed in February 2026, allowing the company to pursue long-term growth strategies in overseas markets without quarterly earnings pressures.